Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
June 07, 2021 17:19 ET | Arvinas Inc.
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
June 03, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas to Present at the UBS Global Healthcare Virtual Conference
May 20, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., May 20, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Signs Lease for New Space Within Downtown Crossing Development in New Haven
May 04, 2021 14:52 ET | Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 04, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 04, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Announces Upcoming Presentations at the American Association for Cancer Research Annual Meeting 2021
April 05, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas to Participate in Upcoming Virtual Investor Conferences
March 10, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 01, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation,...
arvinas logo.jpg
Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day
February 08, 2021 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas logo.jpg
Arvinas, Inc. Announces Exercise of Underwriters’ Option to Purchase Additional Shares
December 28, 2020 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its...